Medical Management of Microscopic Colitis
Based on guidelines from the American Gastroenterological Association.
Treatment
The AGA recommends treatment with budesonide over no treatment for the induction of clinical remission.
The AGA recommends treatment with budesonide over mesalamine for the induction of clinical remission.
In patients in whom budesonide therapy is not feasible, the AGA suggests treatment with bismuth salicylate over no treatment for the induction of clinical remission.
In patients in whom budesonide therapy is not feasible, the AGA suggests treatment with prednisolone (or prednisone) over no treatment for the induction of clinical remission.
In patients in whom budesonide therapy is not feasible, the AGA suggests treatment with mesalamine over no treatment for the induction of clinical remission.
The AGA suggests against combination therapy with cholestyramine and mesalamine over mesalamine alone for the induction of clinical remission.
The AGA suggests against treatment with Boswellia serrata over no treatment for the induction of clinical remission.
The AGA suggests against treatment with probiotics over no treatment for the induction of clinical remission.
For patients with recurrence of symptoms following discontinuation of induction therapy for microscopic colitis, the AGA recommends budesonide for maintenance of clinical remission.
How strong is the AGA's recommendation?
